Impact Biomedical INC

Impact BioMedical Inc. has amended its merger agreement with Dr Ashleys Limited, extending the closing deadline to July 1, 2026, and adjusting share considerations for key parties.

Impact Biomedical Inc. announced that its stockholders approved the election of eight directors, ratified Grassi & Co. as its independent auditor, and approved executive compensation at its 2025 annual meeting.

Impact BioMedical Inc. announced the conversion of Series A Convertible Preferred Stock held by DSS BioHealth Security, Inc. into 60,496,041 shares of common stock.

Impact BioMedical Inc. has settled an outstanding $12 million debt with DSS, Inc. by issuing 31.9 million shares of common stock.

Impact BioMedical Inc. and Dr Ashleys Limited have entered into a Merger and Share Exchange Agreement, which will result in a reverse merger forming a new publicly traded entity, Dr Ashleys Limited, on the NYSE American, aiming to accelerate the market reach of Impact BioMedical's innovative pharmaceutical patents.

Impact BioMedical Inc. reports that DSS, Inc. has withdrawn from the Debt Conversion Agreement due to current market conditions, meaning no shares were issued.

Impact BioMedical reports a net loss of $2.28 million for Q1 2026, a significant increase from the prior year, primarily due to substantial stock-based compensation expenses.

Impact BioMedical reported a significant net loss for Q3 2025, driven by a fair value adjustment on related-party debt, while pursuing strategic acquisitions and a major merger.

Impact BioMedical, Inc. reported a significant increase in net loss for Q2 2025, driven by fair value adjustments on related-party debt and higher operating expenses, raising going concern doubts.

Impact BioMedical's Q1 2025 results reveal an increased net loss compared to Q1 2024, driven by higher operating expenses following its initial public offering.

Impact BioMedical reported a significant increase in net income for the third quarter of 2024, driven by cost-cutting measures and a favorable change in the fair value of embedded derivatives.

Impact BioMedical reported a net loss for the second quarter of 2024, while continuing to focus on its IPO and the monetization of its intellectual property.

Impact BioMedical Inc.'s 2024 annual report highlights its IPO completion, intellectual property expansion, and ongoing development of its technology portfolio despite incurring a net loss.

Impact BioMedical Inc. released its 2023 annual report, detailing its financial status, ongoing research, and strategic partnerships in the biotechnology sector.

IMPACT BIOMEDICAL CFO Todd Macko sold 45,000 shares of common stock in late March 2026 under a Rule 10b5-1 trading plan.

IMPACT BIOMEDICAL Director Jason Grady sold 50,000 shares of common stock for $0.6501 per share on March 23, 2026.

DSS Inc. filed an amended Form 4 to correct its beneficial ownership of Impact Biomedical Inc. common stock following recent sales.

DSS, Inc., a 10% owner and director of IMPACT BIOMEDICAL INC., has reported the sale of its entire beneficial ownership of common stock in two transactions totaling 161,000 shares.

DSS, Inc. reports the sale of 890,800 shares of Impact Biomedical Inc. common stock on April 4, 2025.

Director Chan Heng Fai Ambrose reports the sale of 351,555 common stock shares of Impact Biomedical Inc. by Alset International Limited, a majority-owned subsidiary of Alset Inc.

Impact BioMedical Inc. announces a planned reverse stock split with a ratio between 1-for-12.48 and 1-for-50, approved by majority stockholders to enhance market perception and meet listing requirements.

Impact BioMedical Inc. announces its 2025 Annual Meeting of Stockholders to elect directors, ratify auditors, and hold an advisory vote on executive compensation.

Impact BioMedical Inc. will issue 31.9 million common shares to DSS, Inc. to convert a $12 million debt, making DSS the majority common shareholder.

Impact BioMedical Inc. announces the approval of its 2023 Equity Incentive Plan, reserving up to 5 million common shares for employee and director compensation.

Impact BioMedical Inc. has filed an amendment to its Form S-1 registration statement with the SEC, primarily to update information regarding the expenses associated with the issuance and distribution of securities.

Impact BioMedical's latest S-1/A filing details the terms and conditions of a common stock purchase warrant issued to Revere Securities, LLC.

Impact BioMedical Inc. has filed an amendment to its Form S-1 registration statement related to its proposed initial public offering of common stock and representative warrants.

Impact BioMedical Inc. has filed an amendment to its Form S-1 registration statement, outlining details of a proposed initial public offering and related agreements.

Impact BioMedical Inc. plans to raise approximately $7 million through an initial public offering of 2,000,000 shares of common stock.

Heng Fai Ambrose Chan and his affiliated entities, Alset Inc., Alset International Limited, and Global Biomedical Pte. Ltd., have significantly reduced their beneficial ownership in IMPACT BIOMEDICAL INC. through a series of share sales in late March and early April 2025.

A group of affiliated entities led by Heng Fai Ambrose Chan has significantly reduced its beneficial ownership in IMPACT BIOMEDICAL INC. through recent share sales.